NCT01626352 - Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

April 30, 2017

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Bendamustine

Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.

DRUG

Ofatumumab

Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6

Trial Locations (11)

Woodlands Medical Specialists, Pensacola

Space Coast Cancer Center, Titusville

Florida Cancer Specialists North, St. Petersburg

Florida Cancer Specialists-South, Fort Myers

Tennessee Oncology, PLLC, Nashville

Tennessee Oncology-Chattanooga, Chattanooga

Providence Medical Group, Terre Haute

RHHP/Hope Cancer Center, Terre Haute

Grand Rapids Oncology Program, Grand Rapids

Oklahoma University, Oklahoma City

Cancer Centers of Southwest Oklahoma, Lawton